This study further expands our previous observation demonstrating the usefulness of combination therapy of anti-TNF-alpha and Cyclosporine A in the treatment of rheumatoid arthritis and concurrent hepatitis C virus infection, as well its efficacy and safety in controlling HCV viremia and liver toxicity. Seven patients were included in the study; transaminase levels remained unchanged, HCV RNA serum levels decreased significantly and DAS 28 significantly improved after twelve month follow-up. No side effects were registered.

Efficacy and safety of anti-TNF-alpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection / C. Giannitti, M. Benucci, R. Caporali, S. Manganelli, F. Bellisai, G.D. Sebastiani, M. Galeazzi. - In: INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY. - ISSN 0394-6320. - 22:2(2009 Apr), pp. 543-546. [10.1177/039463200902200233]

Efficacy and safety of anti-TNF-alpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection

R. Caporali;
2009

Abstract

This study further expands our previous observation demonstrating the usefulness of combination therapy of anti-TNF-alpha and Cyclosporine A in the treatment of rheumatoid arthritis and concurrent hepatitis C virus infection, as well its efficacy and safety in controlling HCV viremia and liver toxicity. Seven patients were included in the study; transaminase levels remained unchanged, HCV RNA serum levels decreased significantly and DAS 28 significantly improved after twelve month follow-up. No side effects were registered.
rheumatoid arthritis; HCV; anti TNF-alpha; CsA; Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiviral Agents; Arthritis, Rheumatoid; Cyclosporine; Drug Therapy, Combination; Etanercept; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoglobulin G; Immunosuppressive Agents; Italy; Male; Middle Aged; Pilot Projects; Prospective Studies; RNA, Viral; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Viral Load
Settore MED/16 - Reumatologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
039463200902200233.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 564.58 kB
Formato Adobe PDF
564.58 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/944049
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 21
social impact